Healthy
Mononuclear cells collected
from healthy donors
Cells modification
Modified through a proprietary
process to express “eat me”
signal (PtdSer) on their surface,
while maintaining an intact membrane
Patient
Triggering engulfment into
macrophages via binding to BAI,
TIM4, and stabilin 2, annexin V
Activated macrophage
Homeostatic macrophage
Clinical focus
Our clinical development programs focus on treating solid tumors and sepsis. Our most advanced product candidate, Allocetra™ has demonstrated positive safety, tolerability and efficacy in several clinical trials. In addition to our ongoing late-stage clinical trial in sepsis, we plan on initiating clinical trials of Allocetra™ in solid cancer patients during 2022.
Extensive pre-clinical data
Rich pipeline of registration studies targeting conditional marketing approval
3 primary indications
Recent Publications
2010 | iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-kB dependent blockade,
Gil Amarilyo, Dror Mevorach, et al., European Journal of Immunology
